Catamount Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Catamount Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-7,710	Closed	-$1.47M	–	215
2018 Q4	$1.47M	Sell	7,710 -1,995	-21%	-$346K	1%	18
2018 Q3	$1.87M	Sell	9,705 -60	-0.6%	-$10.7K	0.9%	22
2018 Q2	$1.71M	Buy	9,765 +2,635	+37%	+$408K	0.83%	23
2018 Q1	$1.16M	Buy	7,130 +1,475	+26%	+$241K	0.62%	26
2017 Q4	$847K	Sell	5,655 -9,270	-62%	-$1.37M	0.47%	26
2017 Q3	$2.27M	Buy	+14,925	New	+$2.25M	1.32%	22

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Catamount Wealth Management's VRTX Position: Q1 2019 in Review

Catamount Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2019, closing a stake of 7,710 shares — an estimated $1.47M sold.

Catamount Wealth Management first reported a position in VRTX in Q3 2017 and held it in 6 quarters. The position peaked at $2.27M in Q3 2017. 736 funds tracked by Wall St. Rank hold VRTX as of Q1 2019.

Catamount Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Catamount Wealth Management sold 7,710 Vertex Pharmaceuticals shares in Q1 2019, an estimated $1.47M.
Catamount Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2017 and held it in 6 quarters.
Catamount Wealth Management's Vertex Pharmaceuticals position peaked at $2.27M in Q3 2017.
736 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2019.

Based on Catamount Wealth Management's 13F filing for Q1 2019, filed 3 May 2019.